Search Results - "Zambelli, A."

THE IMPORTANCE OF DEEP GENOTYPING IN CROP BREEDING by Zambelli, A.

“…One of the greatest challenges facing humanity is the development of sustainable strategies to ensure food availability in response to population growth and…”
Get full text

THE IMPACT OF MOLECULAR GENETICS IN PLANT BREEDING: REALITIES AND PERSPECTIVES by Zambelli, A

“…Even when conventional breeding was effective in achieving a continuous improvement in yield, Molecular Genetics tools applied in plant breeding contributed to…”
Get full text

Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer by Gaudio, M., Jacobs, F., Benvenuti, C., Saltalamacchia, G., Gerosa, R., De Sanctis, R., Santoro, A., Zambelli, A.

“…Purpose HER2-low breast cancer (BC) is a novel entity with relevant therapeutic implications, especially in hormone receptor (HR) positive BC. This study…”
Get full text

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors by Kloth, J S L, Pagani, A, Verboom, M C, Malovini, A, Napolitano, C, Kruit, W H J, Sleijfer, S, Steeghs, N, Zambelli, A, Mathijssen, R H J

“…Background: Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval…”
Get full text

Temporal electronic phenotyping by mining careflows of breast cancer patients by Dagliati, A., Sacchi, L., Zambelli, A., Tibollo, V., Pavesi, L., Holmes, J.H., Bellazzi, R.

“…[Display omitted] •A careflow mining approach designed to analyze heterogeneous longitudinal data is proposed.•Temporal electronic phenotyping of EHR and…”
Get full text

Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence by Zambelli, A., Gallerani, E., Garrone, O., Pedersini, R., Rota Caremoli, E., Sagrada, P., Sala, E., Cazzaniga, ME

“…Hormone-receptor positive (HR+), Human-Epidermal-growth Factor negative (HER2-) breast cancer, including the Luminal A and the Luminal B subtypes, is the most…”
Get full text

AurkA controls self-renewal of breast cancer-initiating cells promoting wnt3a stabilization through suppression of miR-128 by Eterno, V., Zambelli, A., Villani, L., Tuscano, A., Manera, S., Spitaleri, A., Pavesi, L., Amato, A.

“…AurkA overexpression was previously found in breast cancer and associated to its ability in controlling chromosome segregation during mitosis, however whether…”
Get full text

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, M., Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

“…[Display omitted] •Triple-negative metastatic breast cancer represents a challenging scenario.•Besides chemotherapy, several novel agents are now available in…”
Get full text

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study by Beltrame, L., Di Marino, M., Fruscio, R., Calura, E., Chapman, B., Clivio, L., Sina, F., Mele, C., Iatropoulos, P., Grassi, T., Fotia, V., Romualdi, C., Martini, P., Noris, M., Paracchini, L., Craparotta, I., Petrillo, M., Milani, R., Perego, P., Ravaggi, A., Zambelli, A., Ronchetti, E., D'Incalci, M., Marchini, S.

“…The majority of patients with stage III–IV epithelial ovarian cancer (EOC) relapse after initially responding to platinum-based chemotherapy, and develop…”
Get full text

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, M., Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

Get full text

Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors by Antonini, S., Pedersini, R., Birtolo, M. F., Baruch, N. L., Carrone, F., Jaafar, S., Ciafardini, A., Cosentini, D., Laganà, M., Torrisi, R., Farina, D., Leonardi, L., Balzarini, L., Vena, W., Bossi, A. C., Zambelli, A., Lania, A. G., Berruti, A., Mazziotti, G.

“…Purpose Trabecular bone score (TBS) is a gray-level textural metric that has shown to correlate with risk of fractures in several forms of osteoporosis. The…”
Get full text

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] by Miglietta, F., Fabi, A., Generali, D., Dieci, M.V., Arpino, G., Bianchini, G., Cinieri, S., Conte, P.F., Curigliano, G., De Laurentiis, Michelino, Del Mastro, L., De Placido, S., Gennari, A., Puglisi, F., Zambelli, A., Perrone, F., Guarneri, V.

Get full text

Solvent and HEMA Increase Adhesive Toxicity and Cytokine Release from Dental Pulp Cells by Massaro, Helder, Zambelli, Lígia F A, Britto, Auriléia A de, Vieira, Rodolfo P, Ligeiro-de-Oliveira, Ana P, Andia, Denise C, Oliveira, Marcelo T, Lima, Adriano F

“…The aim of the present study was to evaluate the effect of the hydroxyethyl-methacrylate (HEMA) concentration and solvent content of dental adhesives on cell…”
Get full text

Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors by Antonini, S., Pedersini, R., Birtolo, M. F., Baruch, N. L., Carrone, F., Jaafar, S., Ciafardini, A., Cosentini, D., Laganà, M., Torrisi, R., Farina, D., Leonardi, L., Balzarini, L., Vena, W., Bossi, A. C., Zambelli, A., Lania, A. G., Berruti, A., Mazziotti, G.

Get full text

Targeting the EWS–FLI1 transcription factor in Ewing sarcoma by Tancredi, R., Zambelli, A., DaPrada, G. A., Fregoni, V., Pavesi, L., Riccardi, A., Burdach, S., Grohar, P. J., D’Incalci, M.

“…Purpose Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and…”
Get full text

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) by Cortesi, L., Venturelli, M., Cortesi, G., Caggia, F., Toss, A., Barbieri, E., De Giorgi, U., Guarneri, V., Musolino, A., De Matteis, E., Zambelli, A., Bisagni, G., Dominici, M.

“…BRCA1/2-related metastatic breast cancers (mBC) are sensitive to DNA-damage agents and show high tumor-infiltrated lymphocytes. We hypothesized that the…”
Get full text

Free mobility of medical oncologists across the European Union: still a false myth by Schiavon, G., Zambelli, A.

Get full text

Patient similarity by joint matrix trifactorization to identify subgroups in acute myeloid leukemia by Vitali, F, Marini, S, Pala, D, Demartini, A, Montoli, S, Zambelli, A, Bellazzi, R

“…Abstract Objective Computing patients' similarity is of great interest in precision oncology since it supports clustering and subgroup identification,…”
Get full text

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study by Cazzaniga, M.E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G.V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M.C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M.R., Vici, P., Zambelli, A., Clivio, L., Torri, V., Alù, M., Ancona, C., Andreis, D., Bajardi, E., Benedetto, C., Berardi, R., Bordin, E., Butti, C., Capri, G., Cicchiello, F., Cocciolone, V., Dester, M., D'Onofrio, L., Febbraro, A., Ferrarini, I., Fotia, V., Gervasi, E., Guaitoli, G., Licata, L., Liscia, N., Mentuccia, L., Miraglio, E., Nicolini, M., Paternò, E., Pedani, F., Pellegrini, D., Petrucelli, L., De Laurentiis, M., Pizzuti, L., Pogliani, C., Riva, F.

“…The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET…”
Get full text

Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis by Fabi, A, Alesini, D, Valle, E, Carbognin, L, Arpino, G, Santini, D, Montemurro, F, Ciccarese, M, Cannita, K, Paris, I, Moscetti, L, De Laurentiis, M, Zambelli, A, La Verde, N, Nisticò, C, Ferretti, G, Gasparro, S, Giannarelli, D, Cognetti, F

Get full text